t
On 27 October 2025, Kromek Group plc granted options to seven directors, with individual grants ranging from 14,352 to 1,500,000 options at exercise prices of 1p or 5.6p; CEO Arnab Basu also exercised 110,000 options at 1p per share. Following the Company's AGM on the same date, Lawrence Kinet and Jerel Whittingham retired from the Board, and Matthew Boyle was appointed as a Non-executive Director. An application was made for the 110,000 new shares to be admitted to AIM by 31 October 2025, resulting in 655,096,840 ordinary shares in issue and 41,247,868 options outstanding (6.3% of enlarged share capital).
| Date | 28 Oct 2025 |
| Time | 07:00:11 |
| Category | Director/PDMR dealings |
| ID | 0188F |
28 October 2025
Kromek Group plc
("Kromek", the "Company" or the "Group")
Grant of Options, PDMR Dealings
and
Total Voting Rights
Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces the following grant of options to, and exercise of options by, directors of the Company.
Grant of options
On 27 October 2025 (the "Grant Date"), the Company granted options over ordinary shares of 1p each in the Company ("Ordinary Shares") to the directors of the Company in consideration for certain bonus awards and salary increases as detailed below. The directors elected to receive options in lieu of cash payments to support the Company's cash position and to further align the interests of the directors with those of shareholders.
|
Director |
Number of options |
Exercise price |
Vesting period(1) |
|
Arnab Basu, CEO |
1,111,375(2) |
1p |
Vest upon issue |
|
469,355(3) (7) |
1p |
234,677 options vest upon issue and the remainder vest in six equal installments on the monthly anniversary of the Grant Date subject to Dr. Basu remaining a director of the Company |
|
|
Berry Beumer, COO & President of Advanced Imaging Division |
1,111,375(2) |
1p |
Vest upon issue |
|
Claire Burgess, CFO |
1,500,000(4) |
5.6p |
50% of the options vest on the second annual anniversary of the Grant Date and 50% vest on the third annual anniversary of the Grant subject to Ms. Burgess remaining a director of the Company |
|
Rakesh Sharma, Chairman |
59,033(5) (7) |
1p |
29,516 options vest upon issue and the remainder vest in six equal installments on the monthly anniversary of the Grant Date subject to Mr. Sharma remaining a director of the Company |
|
Christopher Wilkes, Non-executive Director |
31,104(5) (7) |
1p |
15,552 options vest upon issue and the remainder vest in six equal installments on the monthly anniversary of the Grant Date subject to Mr. Wilkes remaining a director of the Company |
|
Lawrence Kinet, Non-executive Director |
14,352(6) (7) |
1p |
Vest upon issue |
|
Jerel Whittingham, Non-executive Director |
15,552(6) (7) |
1p |
Vest upon issue |
Notes
(1) All of the options, to the extent vested, expire on the tenth annual anniversary of the Grant Date.
(2) Options granted in respect of the delivery of the second milestone under the Company's enablement agreement with Siemens Healthineers and receipt of the associated cash payment, as described in the Company's announcement of 16 September 2025. The quantity of options was calculated based on a price of 5.65p per Ordinary Share, being the average price of the Company's Ordinary Shares on AIM for the three months preceding and three months following the announcement of the Siemens Healthineers transaction on 30 January 2025.
(3) Options granted in lieu of salary increases for the financial years ending 30 April 2025 and 30 April 2026, with the percentage increase matching that given to the Company's employees for the same period.
(4) Options granted as a special bonus for success in securing the Company's new banking facilities and in completing the audit for the financial year ended 30 April 2025. The exercise price represents the average price of the Company's Ordinary Shares on AIM for the period from 12 May 2025, being the date Ms. Burgess joined the Company, to 16 September 2025, being the date of the announcement of the Company's final results for the ended 30 April 2025.
(5) Options granted in lieu of salary increases for the financial year ending 30 April 2026, with the percentage increase matching that given to the Company's employees for the same period.
(6) Options granted in lieu of salary increases for the financial year ending 30 April 2026, with the percentage increase matching that given to the Company's employees for the same period. Mr. Kinet and Mr. Whittingham were granted the options as Non-executive Directors ahead of resigning from their positions at the conclusion of the annual general meeting on 27 October 2025. Accordingly, their options cover the period from 1 May 2025 to their resignation.
(7) The quantity of options was calculated based on a price of 5.8p per Ordinary Share, being the average price of the Company's Ordinary Shares on AIM for the period from 1 May 2025 to 31 July 2025.
Exercise of options
The Company also announces that, on 27 October 2025, Arnab Basu, Chief Executive Officer, exercised options over 110,000 Ordinary Shares at a price of 1p per Ordinary Share.
Following this exercise of options, Dr. Basu has an interest in 3,198,750 Ordinary Shares representing 0.5% of the Company's enlarged issued share capital and holds options over 9,287,308 Ordinary Shares.
Board structure
Following the conclusion of yesterday's annual general meeting, Lawrence Kinet and Jerel Whittingham have retired from the Board and Matthew ("Matt") Boyle has joined as a Non-executive Director of the Company.
Total voting rights
Application has been made to the London Stock Exchange for the 110,000 Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8:00 a.m. on or around 31 October 2025. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.
Following Admission, the total number of Ordinary Shares in issue will be 655,096,840. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. Following the issue of options to directors, the Company has options outstanding over 41,247,868 Ordinary Shares, which following Admission will represent 6.3% of the Company's enlarged issued share capital.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
Enquiries
|
Kromek Group plc |
|
|
Arnab Basu, CEO Claire Burgess, CFO |
+44 (0)1740 626 060 |
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance Tim Redfern - ECM Michael Johnson - Sales |
+44 (0)20 7220 0500
|
|
|
|
|
Gracechurch Group (Financial PR) |
|
|
Harry Chathli/Claire Norbury |
+44 (0)20 4582 3500 |
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.
The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Arnab Basu |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Executive Officer |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
Kromek Group plc |
||||
|
b)
|
LEI
|
213800VLHYXGHEX5VQ48
|
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of 1 penny each |
||||
|
|
|
|||||
|
Identification code |
GB00BD7V5D43 |
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
1. Grants of options 2. Exercise of options |
||||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1. |
1p |
1,111,375 (grant) |
|
|
|
|
|
1. |
1p |
469,355 (grant) |
|
|
|
|
|
2. |
1p |
110,000 (exercise) |
|
|
|
|
|
|
|
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
27 October 2025 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Berry Beumer |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Operating Officer and President of the Advanced Imaging Division |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Kromek Group plc |
|||
|
b)
|
LEI
|
213800VLHYXGHEX5VQ48
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of 1 penny each |
|||
|
|
|
||||
|
Identification code |
GB00BD7V5D43 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1p |
1,111,375 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|||
|
|
|
||||
|
e)
|
Date of the transaction
|
27 October 2025 |
|||
|
f)
|
Place of the transaction
|
Outside a trading venue |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Claire Burgess |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Financial Officer |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Kromek Group plc |
|||
|
b)
|
LEI
|
213800VLHYXGHEX5VQ48
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of 1 penny each |
|||
|
|
|
||||
|
Identification code |
GB00BD7V5D43 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
5.6p |
1,500,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|||
|
|
|
||||
|
e)
|
Date of the transaction
|
27 October 2025 |
|||
|
f)
|
Place of the transaction
|
Outside a trading venue |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Rakesh Sharma |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chairman |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Kromek Group plc |
|||
|
b)
|
LEI
|
213800VLHYXGHEX5VQ48
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of 1 penny each |
|||
|
|
|
||||
|
Identification code |
GB00BD7V5D43 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1p |
59,033 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|||
|
|
|
||||
|
e)
|
Date of the transaction
|
27 October 2025 |
|||
|
f)
|
Place of the transaction
|
Outside a trading venue |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Christopher Wilkes |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-executive Director |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Kromek Group plc |
|||
|
b)
|
LEI
|
213800VLHYXGHEX5VQ48
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of 1 penny each |
|||
|
|
|
||||
|
Identification code |
GB00BD7V5D43 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1p |
31,104 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|||
|
|
|
||||
|
e)
|
Date of the transaction
|
27 October 2025 |
|||
|
f)
|
Place of the transaction
|
Outside a trading venue |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Lawrence Kinet |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-executive Director (at the time of the transaction) |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Kromek Group plc |
|||
|
b)
|
LEI
|
213800VLHYXGHEX5VQ48
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of 1 penny each |
|||
|
|
|
||||
|
Identification code |
GB00BD7V5D43 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1p |
14,352 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|||
|
|
|
||||
|
e)
|
Date of the transaction
|
27 October 2025 |
|||
|
f)
|
Place of the transaction
|
Outside a trading venue |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Jerel Whittingham |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-executive Director (at the time of the transaction) |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Kromek Group plc |
|||
|
b)
|
LEI
|
213800VLHYXGHEX5VQ48
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of 1 penny each |
|||
|
|
|
||||
|
Identification code |
GB00BD7V5D43 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1p |
15,552 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|||
|
|
|
||||
|
e)
|
Date of the transaction
|
27 October 2025 |
|||
|
f)
|
Place of the transaction
|
Outside a trading venue |
|||